Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients

被引:25
作者
Aoki, Kazutaka [1 ]
Nakamura, Akinobu [1 ]
Ito, Satoshi [1 ]
Nezu, Uru [1 ]
Iwasaki, Tomoyuki [1 ]
Takahashi, Mayumi [1 ]
Kimura, Mari [1 ]
Terauchi, Yasuo [1 ]
机构
[1] Yokohama City Univ, Grad Sch Med, Dept Endocrinol & Metab, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan
关键词
alpha GI; miglitol; postprandial glucose; type; 2; diabetes;
D O I
10.1016/j.diabres.2007.01.072
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Miglitol, a pseudomonosaccharide alpha-glucosidase inhibitor (alpha GI), was more effective at reducing blood glucose levels at 30 and 60 min after a meal than voglibose. Speculating that miglitol administered even after the start of a meal may be effective, we evaluated the timing of administration of miglitol on the plasma glucose and serum insulin levels in 13 type 2 diabetic patients. Miglitol was administered in four different intake manners in each patient (control: no mightol; intake 1: just before breakfast; intake 2: 15 min after the beginning of breakfast; intake 3: 30 min after the beginning of breakfast). The area under the curve (AUC) of plasma glucose was significantly decreased under all the intake conditions, as compared with the AUC in the control. The AUC of serum insulin tended to be lower in all the three groups than in the control, although the differences were not statistically significant. Thus, miglitol administered anytime within 30 min after the start of a meal is effective for glycemic control. These results suggest that if patients miss taking miglitol at the beginning of a meal, they can still take the drug until 30 min after starting their meal. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:30 / 33
页数:4
相关论文
共 17 条
[1]
Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
[2]
Asakura T, 1999, JPN J HOSP PHARM, V25, P715
[3]
Baron AD, 1998, DIABETES RES CLIN PR, V40, pS51
[4]
Borch-Johnsen K, 1999, LANCET, V354, P617
[5]
Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[6]
Adherence with pharmacotherapy for type 2 diabetes: A retrospective cohort study of adults with employer-sponsored health insurance [J].
Hertz, RP ;
Unger, AN ;
Lustik, MB .
CLINICAL THERAPEUTICS, 2005, 27 (07) :1064-1073
[7]
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44) [J].
Holman, RR ;
Cull, CA ;
Turner, RC .
DIABETES CARE, 1999, 22 (06) :960-964
[8]
Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients [J].
Johnston, PS ;
Lebovitz, HE ;
Coniff, RF ;
Simonson, DC ;
Raskin, P ;
Munera, CL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (05) :1515-1522
[9]
EFFECTS OF THE CARBOHYDRASE INHIBITOR MIGLITOL IN SULFONYLUREA-TREATED NIDDM PATIENTS [J].
JOHNSTON, PS ;
SANTIAGO, JV ;
CONIFF, RF ;
PISUNYER, FX ;
HOOGWERF, BJ ;
KROL, A .
DIABETES CARE, 1994, 17 (01) :20-29
[10]
Acarbose in the treatment of elderly patients with type 2 diabetes [J].
Josse, RG ;
Chiasson, JL ;
Ryan, EA ;
Lau, DCW ;
Ross, SA ;
Yale, JF ;
Leiter, LA ;
Maheux, P ;
Tessier, D ;
Wolever, TMS ;
Gerstein, H ;
Rodger, NW ;
Dornan, JM ;
Murphy, LJ ;
Rabasa-Lhoret, R ;
Meneilly, GS .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2003, 59 (01) :37-42